Advanced Filters
noise

HIV Clinical Trials

A listing of HIV medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 443 clinical trials
U US GSK Clinical Trials Call Center

Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics

The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA [Ribonucleic Acid] < 50 [cells per milliliter] c/mL) children 6 to less than 12 years of age, …

6 - 12 years of age All Phase 1/2

MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)

This study will examine if at least one dose level of MK-4646 can lower HIV-1 viral load in a person's blood by a certain amount. The goals of this study are to learn about the safety of MK-4646 and if people tolerate it; and how HIV-1 viral load may decrease …

18 - 60 years of age All Phase 1
R Ricardo La Hoz, MD

HIV+ Deceased Donor Heart Transplant Study for HIV+ Recipients

This will be a prospective single-center interventional trial to compare the outcomes of HIV-positive heart transplant recipients by the HIV status of the donor; HIV-positive vs. HIV-negative and learn whether heart organ transplantation from HIV+ deceased donors is as safe and effective in HIV+ recipients as transplants from HIV- deceased …

18 years of age All Phase N/A
S Siderleny Martins

Clinical Trial to Evaluate the Efficacy and Safety of Codivir® in Addition to Standard Antiretroviral Treatment for HIV Infection in Antiretroviral-naïve Participants

The study will begin with a two-week lead-in period (W-2 and W-1), when participants randomized to Codivir® will receive Codivir® 2 mL, 1 subcutaneous injection every day. Participants randomized to Standard Antiretroviral Treatment will wait for the next step. At V0 (W0, D0) all participants will start the antiretroviral treatment …

18 years of age All Phase 2
U US GSK Clinical Trials Call Center

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV

The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV.

18 - 55 years of age All Phase 1
J Jose Licona, MD

Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial.

18 - 60 years of age All Phase 1
B Baptiste HOELLINGER, MD

Missed Opportunities for HIV Screening in General Practice

The number of new HIV diagnoses in France in 2022 is estimated to be between 4,200 and 5,700. Of these diagnoses, 43% of infections were detected at a late stage. The objective of this study is to identify missed opportunities for HIV testing in general practice and to understand the …

18 years of age All Phase N/A
S Sheetal Kassim

Safety and Immunogenicity Study of Three mRNAs Encoding HIV Immunogens in Adult Participants Without HIV and in Overall Good Health in South Africa.

The purpose of this study is to evaluate the safety and immunogenicity of mRNAs encoding HIV immunogens (eOD-GT8 60mer, core-g28v2 60mer, N332-GT5 gp151) in adult participants without HIV and in overall good health in South Africa.

18 - 55 years of age All Phase 1

Vaccine Immunity and Inflammation in the Aging Person Living With HIV

This study will track immune responsiveness to conjugate pneumococcal vaccines over time to help determine how long protection from this vaccine lasts in individuals with chronic medical conditions (in this study - HIV) and with age.

18 years of age All Phase 4
G Gbolahan Ajibola

The Tatelo Plus Study

The purpose of this study is to advance pediatric HIV treatment and cure research by evaluating the impact of a combination of three anti-HIV-1 broadly neutralizing antibodies (bNAbs) or analytic treatment interruption (ATI) on viral reservoir, immune function, and maintenance of HIV suppression in early-treated children.

24 - 25 years of age All Phase 1/2

Simplify language using AI